LUNG Pulmonx Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: LUNG

Price (delayed)

$1.635

Market cap

$69.06M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.3

Enterprise value

$63.52M

?
Relative Growth: Rel. Growth: 35
Relative Strength: Rel. Strength: 23
Relative Valuation: Rel. Valuation: 32
Relative Profitability: Rel. Profitability: 28

Pulmonx Corporation is a commercial-stage medical technology company. The Company is focused on providing planning tools and treatments for obstructive lung disease. Its solutions include Zephyr Valve, Chartis Pulmonary Assessment ...

Highlights
Pulmonx's EPS has increased by 10% YoY and by 2.3% from the previous quarter
The net income has grown by 7% YoY
The company's equity fell by 41% YoY and by 15% QoQ
The quick ratio is down by 7% year-on-year and by 6% since the previous quarter
Sector: Healthcare
Industry: Medical Devices
Website: http://pulmonx.com
Peers: OFIX

Key stats

What are the main financial stats of LUNG

LUNG stock price

How has the Pulmonx stock price performed over time
Intraday
7.57%
1 week
-2.68%
1 month
22.93%
1 year
-46.92%
YTD
-26.02%
QTD
26.74%

Financial performance

How have Pulmonx's revenue and profit performed over time
Revenue
$88.55M
Gross profit
$66.84M
Operating income
-$52.06M
Net income
-$53.21M
Gross margin
75.5%
Net margin
-60.1%
Pulmonx's operating margin has increased by 11% YoY
The operating income rose by 10% year-on-year and by 3% since the previous quarter
Pulmonx's net margin has increased by 8% YoY
The net income has grown by 7% YoY

Price vs fundamentals

How does LUNG's price correlate with its fundamentals

Growth

What is Pulmonx's growth rate over time

Valuation

What is Pulmonx stock price valuation
P/E
N/A
P/B
1.51
P/S
0.77
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.72
Pulmonx's EPS has increased by 10% YoY and by 2.3% from the previous quarter
The P/B is 60% lower than the 5-year quarterly average of 3.5
The company's equity fell by 41% YoY and by 15% QoQ
The price to sales (P/S) is 92% less than the 5-year quarterly average of 9.4 and 20% less than the last 4 quarters average of 0.9
The revenue has contracted by 2.2% from the previous quarter

Efficiency

How efficient is Pulmonx business performance
The company's return on equity fell by 46% YoY and by 12% QoQ
LUNG's return on invested capital is down by 24% year-on-year
The ROA fell by 14% YoY and by 4.2% QoQ
Pulmonx's ROS has increased by 9% YoY

Dividends

What is LUNG's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for LUNG.

Financial health

How did Pulmonx financials performed over time
Pulmonx's total assets is 62% more than its total liabilities
Pulmonx's total assets has decreased by 20% YoY and by 7% from the previous quarter
The quick ratio is down by 7% year-on-year and by 6% since the previous quarter
Pulmonx's debt is 23% higher than its equity
The debt to equity has surged by 68% year-on-year and by 18% since the previous quarter
The company's equity fell by 41% YoY and by 15% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.